drugset
drugset / Trial / NCT05005078

A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV

NCT05005078 ↗

Phase 2 Completed 16 enrolled WinSanTor, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a two-part study of the safety, tolerability, and efficacy of topically administered WST-057 for 16 weeks in subjects with HIV with sensory polyneuropathy.

Timeline

Start
2022-02-24
Primary completion
2023-01-18
Completion
2023-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirenzepine Small molecule 4 % Topical
Subject Pirenzepine Small molecule 4 ml Topical

Indications

peripheral neuropathy